HomeCompareTRSBF vs PLD

TRSBF vs PLD: Dividend Comparison 2026

TRSBF yields 1.22% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRSBF wins by $2.58M in total portfolio value· pulled ahead in Year 10
10 years
TRSBF
TRSBF
● Live price
1.22%
Share price
$2.61
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.08M
Annual income
$7,845,769.56
Full TRSBF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TRSBF vs PLD

📍 TRSBF pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRSBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRSBF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRSBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSBF
Annual income on $10K today (after 15% tax)
$103.69/yr
After 10yr DRIP, annual income (after tax)
$6,668,904.13/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, TRSBF beats the other by $2,200,933.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSBF + PLD for your $10,000?

TRSBF: 50%PLD: 50%
100% PLD50/50100% TRSBF
Portfolio after 10yr
$7.79M
Annual income
$6,551,102.87/yr
Blended yield
84.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TRSBF
No analyst data
Altman Z
6.9
Piotroski
8/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSBF buys
0
PLD buys
0
No recent congressional trades found for TRSBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRSBFPLD
Forward yield1.22%3.18%
Annual dividend / share$0.03$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%74.4%
Portfolio after 10y$9.08M$6.50M
Annual income after 10y$7,845,769.56$5,256,436.18
Total dividends collected$8.96M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRSBF vs PLD ($10,000, DRIP)

YearTRSBF PortfolioTRSBF Income/yrPLD PortfolioPLD Income/yrGap
1$10,944$243.97$11,255$555.24$311.00PLD
2$12,209$499.06$13,062$1,018.59$853.00PLD
3$14,104$1,040.65$15,903$1,926.67$1.8KPLD
4$17,339$2,247.09$20,839$3,823.32$3.5KPLD
5$23,716$5,163.36$30,464$8,166.08$6.7KPLD
6$38,577$13,200.74$52,054$19,457.30$13.5KPLD
7$81,413$40,135.71$109,886$54,188.93$28.5KPLD
8$245,435$158,323.22$304,030$186,451.18$58.6KPLD
9$1,154,758$892,143.08$1,166,125$840,813.32$11.4KPLD
10← crossover$9,081,361$7,845,769.56$6,504,190$5,256,436.18+$2.58MTRSBF

TRSBF vs PLD: Complete Analysis 2026

TRSBFStock

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Full TRSBF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TRSBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSBF vs SCHDTRSBF vs JEPITRSBF vs OTRSBF vs KOTRSBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.